Endo plan administrator targets final-decree filing by December 31 after cutting over $748 million of administrative and priority claims - ElevenFlo
Endo plan administrator targets final-decree filing by December 31 after cutting over $748 million of administrative and priority claims
ElevenFlo ·
Endo's plan became effective April 23, 2024. Plan administrator Patrick J. Bartels, Jr. now expects to apply for a final decree in the remaining cases by December 31, 2026Dkt. 423. He can object to administrative, priority and other secured claims through April 19, 2027Dkt. 419. The next hearing, on December 3, is on the Mesh Trust's motion to dismiss a suit by Australian claimants .
The plan was confirmed March 22, 2024 and became effective April 23, 2024 Dkt. 423. What remains is claims reconciliation, disputes over the plan trusts' claim deadlines and the closing of the last open cases.
On November 2, 2026, plan administrator Patrick J. Bartels, Jr. filed post-confirmation reports for the quarter ended September 30, 2026. Each report gives December 31, 2026 as the expected date for a final-decree application. The parent's report (No. 22-22549) shows no cash disbursements in the quarter and $10,047,061 of cumulative cash disbursements since effectiveness. It also shows $63,710,286 of preconfirmation professional fees approved and paid Dkt. 423.
The claims calendar runs past that target. Four days before the reports were filed, the court extended Bartels's deadline to object to administrative expense, priority and other secured claims through April 19, 2027. The extension is without prejudice to further extensions Dkt. 419. On those dates, a holder of such a claim can face an objection for more than three months after the targeted application. The filings do not say whether Bartels will finish that work before he applies or keep a case open for it.
Disputes over claims against the plan trusts continue separately. The Endo Mesh Trust's motion to dismiss a suit by Australian claimants whose trust claims were disallowed is set for hearing on December 3, 2026 Dkt. 16. A claimant's request to file a late claim against the Endo Opioid Personal Injury Trust is in supplemental briefing. The trustee's submission was due November 18 and any response is due November 25 Dkt. 418.
Claim objections have removed more than $748 million of administrative and priority claims
About 900 proofs of claim assert administrative expense, non-IRS priority tax, priority non-tax or other secured claims, which the plan administrator calls SAP Claims. In his October 14, 2026 extension motion, Bartels reported that ten omnibus objections had resolved more than 730 of those claims and reduced the pool by over $748 million. He does not expect to file more omnibus objections. He may still object to individual claims, including claims filed after the bar dates Dkt. 416. The court granted the 180-day extension on October 29, 2026 Dkt. 419.
The amounts allowed and paid so far are small. The parent's September 2026 report shows plan payments of $17,044 on $20,032 of allowed administrative claims, $14,059 on secured claims and $217,990 on priority claims. Each class has 100% anticipated recovery. The report shows no allowed or paid general unsecured claims Dkt. 423. Claims are also being settled one at a time. A stipulated order entered September 30, 2026 allowed the Oregon Department of Human Services an administrative expense claim of $9,992.45 against Astora Women's Health, LLC. The allowance fully resolves six claims and is payable within ten business days of entry Dkt. 413.
Twenty-one debtor cases are closed and only the parent reports disbursements since effectiveness
On November 18, 2025 the court entered a final decree on the docket captioned Branded Operations Holdings, Inc., et al. (Case No. 22-22608). It closed 21 debtor cases, including Par Pharmaceutical, Inc. (22-22546), Endo Pharmaceuticals Inc. (22-22590) and Endo Health Solutions Inc. (22-22573) Dkt. 22. All pending and future matters for every debtor, including claim objections, are now handled in the remaining cases. Any party may seek to reopen a closed case for cause under section 350(b). The right to dispute claims filed in any of the cases is preserved.
Post-confirmation reports for the quarter ended September 30, 2026, filed November 2, 2026
Trust claimants are contesting the deadlines the plan trusts enforce
Australian mesh claimants challenge the Mesh Trust's HIPAA-release disallowance
Jodie Philipsen and Janice Seymour, suing for similarly situated Australian mesh claimants, seek declaratory and injunctive relief in an adversary proceeding over the Endo Mesh Trust's claims process. The court denied their preliminary-injunction motion on August 19, 2026. After a September 22 status conference, it approved a consent schedule on October 2, 2026 Dkt. 13. On October 20, 2026, Mesh Trustee Heather Barlow moved to dismiss the amended complaint with prejudice Dkt. 16.
The trustee argues that the trust documents required a HIPAA release and gave claimants several chances to cure through March 20, 2025. She says the plaintiffs never submitted the release, so their claims were automatically disallowed the next day. She also argues laches: the plaintiffs sued about fifteen months after the cure deadline Dkt. 17. Objections were due November 10, 2026. Replies are due November 30, and the hearing is set for December 3 at 10:00 a.m. By agreement, the ruling will bind all claimants represented by R3M Law, LLP or Shine Lawyers Pty Ltd Dkt. 16.
A late opioid personal injury trust claim awaits supplemental briefing
On September 16, 2026, Damani Dunbar moved for leave to file a late claim against the Endo Opioid Personal Injury Trust. Trustee Edgar C. Gentle, III objected on October 8, 2026 Dkt. 414. According to the trustee, personal injury claimants had to file a bankruptcy proof of claim by July 7, 2023. They then had to file a separate trust claim between April 23 and May 23, 2024. He says emails with the trust notice went to the address on Dunbar's proof of claim on April 2 and May 17, 2024, and neither was returned. He also argues that allowing late claims would burden a trust that has finite assets and pays by formula.
On October 29, 2026 the court directed the trustee to file more information without deciding the motion. The trustee must address what notice was physically mailed to Dunbar and whether the court approved the email-and-publication notice procedures. He must also give the legal basis for finding no excusable neglect Dkt. 418. The submission was due November 18, 2026 and any response is due November 25. The court may rule without another hearing.
A claimant who returned a trust distribution check seeks leave to file
Charles Elliott Anderson, Jr. is subject to a pre-filing injunction entered March 20, 2026 in Adversary Proceeding No. 26-7005. On November 13, 2026 he applied for leave to file a standalone motion about what he describes as PI Trust Check No. 001049 Dkt. 30. By his account, the check was dated October 30, 2026 for $1,618.51. That is the net of a $1,950 gross award after a $331.49 fee he says was not itemized. He says he voided the check without endorsing it and returned it by certified mail on November 9. He also says the trust told him that claimants appealing non-GUC release determinations would not be paid until their appeals were resolved. His proposed order asks the court to confirm the check's rejection and to give directions on cancellation and disputed-fund reserves. The application set a response period through November 17, 2026. If his account is accurate, the trust was issuing award checks by late October 2026. It was also holding payment for claimants whose appeals of release determinations were pending.
The GUC Trust lost its insurance coverage suit against Travelers over the opioid claims
The Endo General Unsecured Creditors' Trust sued insurers for coverage of the opioid lawsuits brought against Endo by governments, third-party payors and individuals. On February 10, 2026 the Eastern District of Pennsylvania granted summary judgment to Travelers in that action, Dundon v. ACE Prop. & Cas. Co., No. 24-cv-4221. The source is an announcement by Simpson Thacher & Bartlett LLP, Travelers' counsel stblaw.com: Simpson Thacher Wins Summary Judgment In Coverage Dispute ... (outside source). The firm says the court held that the policies' products exclusion barred coverage for all of the opioid lawsuits, including claims over Endo's alleged unbranded promotion. It says the court also held, in the alternative, that the government and third-party-payor suits did not allege damages because of bodily injury, as the policies require. The announcement covers Travelers' policies only.
Endo filed with approximately $8.15 billion of funded debt, most of it secured
Endo International plc and its debtor affiliates filed chapter 11 petitions in the Southern District of New York on August 16, 2022 Dkt. 1. Endo is a specialty pharmaceutical company headquartered in Dublin, Ireland, with U.S. operations in Malvern, Pennsylvania. Its segments are branded pharmaceuticals, sterile injectables, generic pharmaceuticals and international pharmaceuticals.
Mark Bradley's first-day declaration reported approximately $8,147.8 million of consolidated funded debt at the petition date. The debt sat under one credit agreement, made up of a revolving credit facility and a term loan, plus four series of secured notes and four series of unsecured notes Dkt. 38 · p. 10. About $1.345 billion was unsecured notes Dkt. 38 · p. 20. The secured debt was mostly first lien, plus $940.6 million of second lien notes. The declaration put funded debt of approximately $8.15 billion at June 30, 2022 at about 7x last-twelve-month adjusted EBITDA of about $1.22 billion. It was more than 10x anticipated 2022 EBITDA of about $775 million, before counting any contingent liabilities Dkt. 38 · p. 22.
The debtors stipulated to the secured debt in the cash collateral orders. They agreed they owed not less than $277.2 million of revolving loans and $1.975 billion of term loans Dkt. 535 · p. 5. They also agreed they owed not less than $940.59 million of second lien notes plus accrued interest Dkt. 535 · p. 11.
Ten instruments made up the debtors' approximately $8.15 billion of funded debt at the petition dateApproximate outstanding principal as of August 16, 2022, from the first-day declaration's funded-debt table. Accrued interest is excluded.
First lien
Second lien
Unsecured
Revolving credit facilityVarious$277.2M
Term loan facilityMar. 2028$1,975.0M
5.875% senior secured notes due 2024Oct. 2024$300.0M
Consensual use of cash collateral, not a DIP loan, funded the case
The debtors moved to use cash collateral on August 17, 2022 Dkt. 17. The court entered an interim order on August 19, 2022 Dkt. 92. Computershare Trust Company, N.A. joined the Ad Hoc First Lien Group's reply in support of the motion Dkt. 377. First lien lenders outside the restructuring support agreement objected to the form of the proposed order Dkt. 393. The court entered a final order on October 20, 2022 Dkt. 499. It entered an amended final order on October 27, 2022, with the consent of the first lien and second lien notes secured parties Dkt. 535. The debtors filed an approved budget under the amended order on May 30, 2023 Dkt. 2130.
A sale process for substantially all assets came before the plan
The debtors asked the court to approve bidding procedures, certain transaction steps and a sale of substantially all of their assets. On February 10, 2023 the court allowed counsel to the Ad Hoc Group of Unsecured Noteholders to offer evidence and be heard on that motion Dkt. 1304. On August 2, 2023 it approved a stipulation resolving one objection to the bidding procedures and sale motion Dkt. 2574.
Four more affiliates filed petitions in May 2023. Operand Pharmaceuticals Holdco II Limited and Operand Pharmaceuticals Holdco III Limited filed on May 25 Dkt. 1Dkt. 1. Operand Pharmaceuticals II Limited and Operand Pharmaceuticals III Limited filed on May 31 .